# IRF1 is a context-dependent homeostatic gatekeeper of basal immunity and antiviral readiness

**Authors:** Eyal Zoler, Irina Miodownik, Shifra Ben-Dor, Daniel Harari, Jiri Zahradnik, Ariel Afek, Gideon Schreiber

PMC · DOI: 10.1016/j.jbc.2025.111118 · The Journal of Biological Chemistry · 2025-12-30

## TL;DR

This study reveals how IRF1 regulates immune responses and antiviral readiness in cells, depending on its abundance and context.

## Contribution

The paper introduces a novel energy-normalized binding matrix for IRF1 to predict promoter-binding affinities beyond standard motifs.

## Key findings

- IRF1 KO increases antiviral gene transcripts through upregulation of other IRF genes.
- IRF1 overexpression induces antiviral protection via secretion of IFN-α subtypes.
- IRF1 binding potential can be predicted across genomic contexts using a new computational model.

## Abstract

Interferon regulatory factor 1 (IRF1) plays a pivotal role in interferon (IFN) signaling. Here, we dissect the impact of IRF1 on gene transcription regulation in HeLa cells, by targeted knockout (KO) or overexpression of IRF1. IRF1 KO partially diminished IFN-γ but not IFN-β induced gene regulation. IRF1 KO did show a homeostatic role in basal transcript abundance, including increasing the abundance of antiviral gene transcripts, apparently through increased expression of other IRF genes. IRF1 overexpression induced potent antiviral protection, which is mediated by secretion of type I IFN proteins, particularly of IFN-α subtypes, which expression is driven by IRF1. This paracrine effect was confirmed by transcriptomics, cytokine profiling, and mass spectrometry. Surprisingly, antiviral protection was observed also in JAK1 KO or ruxolitinib-treated cells but not in type I IFN receptor KO cells, suggesting the involvement of noncanonical signaling pathways. Hierarchical clustering of RNA-seq data revealed distinct IFN-independent gene clusters activated or repressed by IRF1, including pathways related to adaptive immunity and T cell function. Using protein-binding microarrays and predictive modeling, we generated an energy-normalized binding matrix for IRF1, enabling sequence-specific prediction of promoter-binding affinities beyond classical consensus motifs. This approach allows estimation of IRF1-binding potential across diverse genomic contexts as validated for the IFIT2 gene promoter by a reporter assay. Evaluating the biological significance of our study, we show that IRF1 abundance varies by 10,000-fold between cell lines, with positive correlations of IRF1 with the abundance of gene transcripts involved in antiviral and immune-driving activities.

## Linked entities

- **Genes:** IRF1 (interferon regulatory factor 1) [NCBI Gene 3659], IFNG (interferon gamma) [NCBI Gene 3458], IFNB1 (interferon beta 1) [NCBI Gene 3456], IFN1@ (interferon, type 1, cluster) [NCBI Gene 3438], JAK1 (Janus kinase 1) [NCBI Gene 3716], IFIT2 (interferon induced protein with tetratricopeptide repeats 2) [NCBI Gene 3433]
- **Chemicals:** ruxolitinib (PubChem CID 17754772)

## Full-text entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IRF1 (interferon regulatory factor 1) [NCBI Gene 3659] {aka IMD117, IRF-1, MAR}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, JAK1 (Janus kinase 1) [NCBI Gene 3716] {aka AIIDE, JAK1A, JAK1B, JTK3}, IFIT2 (interferon induced protein with tetratricopeptide repeats 2) [NCBI Gene 3433] {aka G10P2, GARG-39, IFI-54, IFI-54K, IFI54, IFIT-2}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}
- **Chemicals:** Ruxolitinib (MESH:C540383)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12887176/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12887176/full.md

## References

112 references — full list in the complete paper: https://tomesphere.com/paper/PMC12887176/full.md

---
Source: https://tomesphere.com/paper/PMC12887176